The salient point is that GILD dropped GS-9669 in phase-3 trials, but has now resurrected GS-9669 in phase-2 trials. GILD clearly has a more positive viewpoint on the utility of a non-nuke in an all-DAA regimen, which is why I said they’re borrowing a page from ABBV/ENTA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.